Royalty Pharma plc Q2: Beat And Raise Reaffirm Our Buy Rating

Solskin On 08/08/2024, Royalty Pharma plc (NASDAQ:RPRX) presented its Q2 earnings. Following a solid Q1, the company raised its 2024 outlook, with Portfolio Receipts expected to achieve $2.7/2.75 billion results. We positively view this announcement; however, today, we decided to focus on an ongoing downside. Downside Protection In our initiation of coverage, we reported how the Vertex franchise is one of the most significant portfolio receipt contributors. In detail, we explained: The cystic fibrosis franc ...